GSK granted option on pneumococcal vaccine proteins
This article was originally published in Scrip
Executive Summary
The Israeli start-up Protea Vaccine Technologies has entered a collaboration and option agreement that grants GlaxoSmithKline Biologicals the option to obtain an exclusive licence to a set of Protea’s conserved pneumococcal proteins for the development and commercialisation of a universal protein-based Streptococcus pneumoniae vaccine. Protea is affiliated with another Israeli vaccine firm NasVax.